IL5 and rheumatoid arthritis: However, this idea has recently been challenged with evidence that anti-IL-5 treatment depletes all populations of eosinophils.18 Whether this distinction would result in a different pattern of adverse effects in patients remains unclear, notably as the patient who developed RA in this report was receiving mepolizumab.